Search

Position of EHA on Clinical Trials

 

The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.

Read more

Meet Ton Hagenbeek, our May volunteer of the month

Anton Hagenbeek began as EHA Volunteer when EHA was only starting out. Below you will read more about his motivations and invites fresh blood to support the organization.

Read more

Meet Ton Hagenbeek, our May volunteer of the month

Anton Hagenbeek began as EHA Volunteer when EHA was only starting out. Below you will read more about his motivations and invites fresh blood to support the organization.

Read more

First CMML guidelines produced by EHA, now available

Chronic myelomonocytic leukemia (CMML) is a rare disease with overlapping features of two categories of bone marrow and blood cell disorders that poses challenges in clinical management.

Read more

EHA donates €250,000 to Médecins Sans Frontières

The EHA Board is actively implementing support actions to hematologists and hematology patients in Ukraine and to those who are forced to leave the country.

Read more

Position of EHA on Access to Medicines

 

There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.

Read more

Genetic Predisposition to Blood Cancer (Rare diseases)

The objectives of the group are:

Share and extend clinical knowledge on the diagnosis and treatment of hematologic malignancies with germline predisposition.

Read more

Call for urgent action on medicine shortages in Europe

Medicine shortages are an increasing problem across Europe, posing a severe threat to patient outcomes and patient safety. In a new position paper the European Public Health Alliance (EPHA) presents nine recommendations for addressing the shortages crisis.

Read more